Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteria

Diagnostic Microbiology and Infectious Disease

Volumn 54, Issue 4, 2006, Pages 305-310

  Kerns, Robert J ^a   Rybak, Michael J ^b   Cheung, Chrissy M ^b  

^a UNIVERSITY OF IOWA   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Antimicrobials; Fluoroquinolone; Resistance; Susceptibility testing

Indexed keywords

CIPROFLOXACIN; DIMER; MONOMER; NORFLOXACIN; PIPEMIDIC ACID; PIPERAZINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; CROSS LINKING; DRUG ACTIVITY; DRUG SENSITIVITY; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; VANCOMYCIN RESISTANT ENTEROCOCCUS;

CIPROFLOXACIN; DIMERIZATION; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; NORFLOXACIN;

EID: 33645858260     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.11.004     Document Type: Article

References (14)

1. Drlica K. Mechanism of fluoroquinolone action. Curr. Opin. Microbiol. 2 (1999) 504-508
2. Drlica K., and Malik M. Fluoroquinolones: action and resistance. Curr. Top. Med. Chem. 3 (2003) 249-282
3. Emmerson A.M., and Jones A.M. The quinolones: decades of development and use. J. Antimicrob. Chemother. 51 Suppl. 1 (2003) 13-20
4. Gould K.A., Pan X.S., Kerns R.J., and Fisher L.M. Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48 (2004) 2108-2115
5. Hooper D.C. Clinical applications of quinolones. Biochim. Biophys. Acta 1400 (1998) 45-61
6. Hooper D.C. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31 Suppl. 2 (2000) 24-28
7. Kaatz G.W. Bacterial efflux pump inhibition. Curr. Opin. Investig. Drugs 6 (2005) 191-198
8. Kerns R.J., Rybak M.J., Kaatz G.W., Vaka F., Cha R., Grucz R.G., Diwadkar V.U., and Ward T. Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of Staphylococcus aureus. Bioorg. Med. Chem. Lett. 13 (2003) 1745-1749
9. Kerns R.J., Rybak M.J., Kaatz G.W., Vaka F., Cha R., Grucz R.G., and Diwadkar V.U. Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of Staphylococcus aureus. Bioorg. Med. Chem. Lett. 13 (2003) 2109-2112
10. Li X.Z., and Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 64 (2004) 159-204
11. Morais Cabral J.H., Jackson A.P., Smith C.V., Shikotra N., Maxwell A., and Liddington R.C. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388 (1997) 903-906
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. 6th ed. (2003), NCCLS, Wayne (PA)
13. Pan X.S., and Fisher L.M. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41 (1997) 471-474
14. Poole K. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother. 56 (2005) 20-51